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4 
Abstract  
 
Vaccines are recognised as a highly cost effective tool for preventing infectious diseases. 
They are derived from biological sources and due to the complexity of composition and 
heterogeneity of products, vaccine lots undergo legally required quality control before 
they are released. Traditionally, laboratory animals have played an important role in 
quality control of vaccines and still, many laboratory animals are used in Europe for this 
purpose. Over the last decades, Replacement, Reduction and Refinement (3Rs) methods 
to classical animal tests have been developed by control authorities, academia and 
vaccine manufacturers.  
The purpose of this report is to inform the EURL ECVAM stakeholders on ongoing 
activities in development and validation of 3Rs methods for the quality control of 
vaccines for human use. The focus of the report is on methods for lot release testing 
(e.g. safety, pyrogenicity, potency) and projects related to the implementation of the 
consistency approach to established vaccines such as diphtheria, tetanus, pertussis and 
rabies vaccines.  
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1. Introduction  
Vaccines are recognised as a highly cost effective tool for preventing infectious diseases. 
Their importance is likely to increase in the future given the emergence of antibiotic-
resistant strains of bacteria and viral infections.  
Vaccines are derived from biological sources and due to the complexity of composition 
and heterogeneity of products, vaccine lots undergo legally required quality control 
before they are released (EC, 2001). Quality control tests are described in the marketing 
authorisation for a given product and granted by the competent authorities. Changes to 
the marketing authorisation, e.g. use of a different method for the lot testing, have to be 
approved by the competent authorities. 
In Europe, lot quality control is performed by the manufacturer and may additionally be 
performed by an Official Medicines Control Laboratory as laid down in the EU guidelines 
on Official Control Authority Batch Release 1 . Traditionally, laboratory animals have 
played an important role in quality control of vaccines and still, many laboratory animals 
are used in Europe for this purpose.  
Over the last decades, Replacement, Reduction and Refinement (3Rs) methods to 
classical animal tests have been developed by control authorities, academia and vaccine 
manufacturers. Milne and Buchheit (2012) provide an overview of 3Rs methods which 
have been incorporated into European Pharmacopoeia (Ph.Eur.) monographs after their 
formal validation under the umbrella of the Biological Standardisation Programme2,3,4 run 
by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and co-
sponsored by the Council of Europe and the European Commission.  
The purpose of this report is to inform the EURL ECVAM stakeholders on ongoing 
activities on the development and validation of 3Rs methods for the quality control of 
vaccines for human use. The focus of the report is on methods for lot release testing 
(e.g. safety, pyrogenicity, potency) and projects related to the implementation of the 
consistency approach to established vaccines such as diphtheria, tetanus, pertussis and 
rabies vaccines.  
  
                                           
1 https://www.edqm.eu/en/Human-OCABR-Guidelines-1530.html  
2 http://www.edqm.eu/en/Biological-Standardisation-Programme-mission-60.html  
3 http://www.edqm.eu/en/BSP-Work-Programme-609.html  
4 https://www.edqm.eu/en/BSP-programme-for-3Rs-1534.html 
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2. Consistency approach 
In order to apply the consistency approach in vaccine production and quality control, it is 
necessary that the vaccine is thoroughly characterised, the crucial characteristics and 
associated parameters for quality (e.g. safety and efficacy) known and the tools for 
monitoring them in place via a quality system (e.g. Good Manufacturing Practice). By 
this, characteristics of a new lot of a vaccine can be compared to those of a reference lot 
(clinical lot) which has been shown to be safe and efficacious.  
The consistency approach is already in place for the newer, well-defined vaccines, e.g. 
human papilloma virus vaccine and polysaccharide conjugate vaccines such as 
meningococcal, Haemophilus type B, and pneumococcal vaccines.  
How the consistency approach could be applied to established vaccines (i.e. vaccines 
which are less well-defined since they are produced by inactivation or attenuation of a 
virulent microorganism or by detoxification of the toxin thereof) was the topic of several 
workshops organised by EURL ECVAM (Metz et al., 2007a; Hendriksen et al., 2008) and 
co-organised with the European Partnership for Alternative Approaches to Animal Testing 
(EPAA; De Mattia et al., 2011). As a follow-up of the latter, EPAA launched in 2011 a 
project to develop the consistency approach for established human and veterinary 
vaccines: Application of the 3Rs and the Consistency Approach for Improved Vaccine 
Quality Control. Within the framework of this project a series of meetings and workshops 
on specific vaccine groups were held with the aim to discuss the consistency approach 
and its implementation in more detail with experts from regulatory bodies, 
manufacturers and academia. De Mattia et al. (2015) provide a general description of 
the project, summaries of meetings, workshops and discussions on possibilities to 
implement the consistency approach for the four priority vaccine groups (diphtheria, 
tetanus and acellular pertussis vaccines; human rabies vaccines; veterinary rabies 
vaccines and clostridial vaccines). Section 5.4 of this report describes one of the 
activities launched within this EPAA project aiming at replacement of an in vivo test for 
potency testing of human rabies vaccines.  
The potential of the consistency approach in vaccine quality control is underlined by the 
recent call5 for proposals within the Innovative Medicines Initiative 2 (IMI 2) programme. 
The aim is to develop/identify non-animal based techniques for vaccine characterisation 
and parameters being critical for the vaccine quality. In addition, aspects of validation 
and promotion to regulatory acceptance should be addressed6.  
The IABS conference on The consistency approach and alternative methods: towards 
non-animal based testing in vaccine development and QC took place on 16-18 
September 2015 (Egmond aan Zee, NL). Further information on the conference is 
available on the conference website7 and relevant presentations are summarised in the 
following sections.  
The Ph.Eur. states in the Section General Notices that a manufacturer needs to 
demonstrate that a product is in compliance with Pharmacopoeia quality. However, this 
does not imply that all tests in a monograph need to be performed. A manufacturer 
could demonstrate that a product is of Pharmacopoeia quality "…on the basis of its 
design, together with its control strategy and data derived, for example, from validation 
studies of the manufacturing process." By including the statement "… manufacturers 
may consider establishing additional systems to monitor consistency of production. With 
the agreement of the competent authority, the choice of tests performed to assess 
compliance with the Pharmacopoeia when animal tests are prescribed is established in 
such a way that animal usage is minimised as much as possible." Ph.Eur. encourages the 
                                           
5 http://www.imi.europa.eu/content/imi-2-call-3-1 
6 Grant negotiations with the VAC2VAC consortium started in December 2015 
7 http://www.consistency-congress.org/ 
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use of 3Rs methods and the implementation of the consistency approach (EDQM, 
2015a). 
 
3. Safety tests 
In general, there are two types of safety tests, specific safety tests associated with 
properties of a given vaccine (discussed under 3.2-3.5) and general safety tests to 
detect non-specific contaminations (also called abnormal toxicity test or test for 
innocuity). 
 
3.1 Abnormal toxicity test 
The abnormal toxicity test (ATT) is a general safety test (using mice and guinea pigs) 
which is intended to detect non-specific contaminants causing adverse effects (EDQM, 
2015b). After introduction of Good Manufacturing Practice and stringent quality criteria 
for the starting materials, the relevance of this test was questioned (Hendriksen et al., 
1994). As a follow-up of the outcome of a retrospective analysis of ATT data carried out 
by the Paul-Ehrlich-Institut (Germany; Duchow et al., 1994; Krämer et al., 1996) and an 
enquiry launched by EDQM (EDQM, 1996), the ATT was deleted as lot release test from 
Ph.Eur. monographs for human vaccines and completely removed from all monographs 
for sera and immunoglobulins for human use as well as for immunobiologicals for 
veterinary use (Schwanig et al., 1997). At present (status 2015), 36 European 
Pharmacopoeia monographs for human vaccines still stipulate under General Provisions 
in the Production section that "The production method is validated to demonstrate that 
the product, if tested, would comply with the test for abnormal toxicity for immunosera 
and vaccines for human use (2.6.9.)" (EDQM, 2015c).  
Despite the deletion of the ATT as a lot release test in Europe, manufacturers producing 
for the global market may still perform the ATT, since it is stipulated by international 
requirements (e.g. World Health Organization [WHO]) and national requirements (e.g. 
Russia, China, Japan, Argentina, Mexico). However, recently revised WHO 
recommendations (for example, hepatitis B vaccines, WHO, 2013a; diphtheria vaccines, 
WHO, 2014a; tetanus vaccines, WHO, 2014b) now state that the test for innocuity "… on 
the final lot may be omitted from routine lot release once the consistency of production 
has been demonstrated" subject to approval of the national regulatory authority. Also, 
other countries allow waivers of the ATT (e.g. India, personal communication) or are 
moving towards deletion of the ATT (e.g. Brazil, personal communication). Only recently, 
US FDA revocated the general safety test (GST), since "GST requirements are no longer 
appropriate to help ensure the safety, purity, and potency of licensed biological 
products" (US FDA, 2015).  
Deletion of the ATT/GST/test for innocuity from regulatory requirements was one of the 
topics discussed at a recent EPAA workshop (see Section 7.2 of this report). 
 
3.2 Absence of toxin and irreversibility of toxoid for tetanus 
vaccines 
The test for absence of toxin and irreversibility of toxoid is stipulated by Ph.Eur. 
monograph for tetanus vaccines for human use (EDQM, 2015d) or combined vaccines 
with a tetanus component to ensure complete and stable inactivation of tetanus toxin 
after detoxification with formaldehyde. The test is carried out in guinea pigs, which 
would develop signs of tetanus disease in the presence of active tetanus toxin.  
Behrensdorf-Nicol et al. (2013) have developed a promising in vitro method, the so-
called BINACLE (binding and cleavage) assay. It mimics two important functional 
properties of intact tetanus toxin molecules: a) their binding via the heavy chain to 
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specific receptors and b) the proteolytic activity of the light chain, namely the cleavage 
of synaptobrevin-2. Other proposed in vitro methods (Leung et al., 2002; Kegel et al., 
2007) only capture the second step and can therefore not discriminate between active 
and detoxified tetanus toxin (Behrensdorf-Nicol et al., 2008; Behrensdorf-Nicol et al., 
2014). After successful transfer to several laboratories and promising results with regard 
to reproducibility (Behrensdorf-Nicol et al., 2014), validation of the BINACLE assay is 
ongoing under the umbrella of the EDQM BSP. 
Rajagopal et al. (2015) are developing a functional cell-based assay covering important 
stages of in vivo tetanus toxin action: toxin binding to the cell surface, endocytosis, 
translocation of the toxin light chain, and enzymatic cleavage of the intracellular target: 
vesicular associated membrane protein-2. Preliminary results show that neuronal cells 
differentiated from pluripotent mouse embryonic stem cells can be used to detect active 
tetanus toxin and their sensitivity is comparable to the current in vivo assay.  
 
3.3 Residual pertussis toxin and irreversibility of pertussis 
toxoid for acellular pertussis vaccines 
The test for residual pertussis toxin and irreversibility of pertussis toxoid (EDQM, 2015e) 
is stipulated by the Ph.Eur. monograph for acellular pertussis vaccines as in-process test 
and for lot release to detect active pertussis toxin (EDQM, 2015f). For in-process testing, 
manufacturers use the in vitro Chinese Hamster Ovary (CHO) cell assay, which is based 
on the observation that in the presence of active pertussis toxin CHO cells grow within 
48 h in clusters (Gillenius et al., 1985). The CHO assay cannot however be used for the 
testing of adjuvanted acellular pertussis vaccines due to the inherent cytotoxicity of 
adjuvants. The only currently accepted assay for residual pertussis activity testing of 
adjuvanted acellular pertussis is the histamine sensitisation (HIST) assay carried out in 
mice (EDQM, 2015e; WHO, 2013b). It is based on the fact that mice get more sensitive 
to the effect of histamine when exposed to active pertussis toxin. Sensitised mice die 
when challenged with a normally non-lethal histamine dose (Corbel and Xing, 2004). 
There are several variations of the HIST protocols in use and regulatory requirements 
differ. In general, the assay is considered to have a high intra- and inter-laboratory 
variability and in order to meet the statistical requirements for a valid assay, several 
repetitions are often necessary (Bache et al., 2012; Isbrucker, 2012).  
Over the last 15 years, an increasing number of possible alternatives to the HIST have 
been developed, which can be divided into three groups: a) assays that measure a single 
biochemical function of pertussis toxin, e.g. enzymatic activities or binding (Cyr et al., 
2001; Gomez et al., 2006; Gomez et al., 2007; Isbrucker et al., 2010; Xing et al., 
2012); b) in addition to the CHO assay, other cell-based assays that measure the whole 
pertussis toxin function (Bache et al., 2012; Hoonakker et al., 2010, 2015; Isbrucker, 
2012) and c) assays that measure biomarkers, i.e. effects on the transcription profile of 
human cells after pertussis toxin exposure (Vaessen et al., 2013; Vaessen et al., 2014). 
As a follow-up of a workshop organised at the Paul-Ehrlich-Institut in 2011, the 
international "Working Group for Alternatives to HIST" was established bringing together 
manufacturers, regulatory bodies and academia (Bache et al., 2012). This working group 
organised a collaborative study (under the umbrella of the BSP114 project) involving 12 
laboratories. It aimed at comparing the sensitivity of several in vitro methods under 
development or in use as in process controls by manufacturers (Isbrucker et al., 2014). 
Participants received seven vaccines, pertussis toxin reference preparation and agreed 
protocols for sample preparation (e.g. spiking of vaccines with pertussis toxin, test 
concentrations, desorption of pertussis toxin) and were asked to test at least three of 
the vaccines with their assay(s). The results of the study were presented and discussed 
at the International Workshop on Alternatives to the Murine Histamine Sensitization Test 
(HIST) for Acellular Pertussis Vaccines: State of the Science and the Path Forward (28-
29 November 2012) organised by the National Toxicology Program Interagency Center 
for the Evaluation of Alternative Toxicological Methods (NICEATM), the Interagency 
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Coordinating Committee on the Validation of Alternative Methods (ICCVAM), and their 
International Cooperation on Alternative Test Methods (ICATM) partners (Isbrucker et 
al., 2014). There was agreement that biochemical assays are useful to monitor pertussis 
toxin activity; however, since they only capture a single function of the pertussis toxin, 
preference was given to the further development of the cell-based assays capturing the 
full function of the pertussis toxin. At the time of the workshop, the most promising cell-
culture based assays were: the cAMP assay (Hoonakker et al., 2010) and the modified 
CHO clustering assay using a porous cell culture insert to prevent contact of the cells 
with the adjuvant (Isbrucker et al., 2014).  
As a follow-up of the workshop, the "Working Group for Alternatives to HIST" organised 
a second collaborative study under the umbrella of the BSP114 project, which evaluated 
two CHO cell-based methods with acellular pertussis vaccines representative for the 
market. As in the first study, pertussis reference preparation has been used for the 
spiking of vaccine samples. The study took place during 2014. The results have been 
reviewed and discussed by regulators and manufacturers at the international workshop 
In search of acceptable alternatives to the murine histamine sensitization test (HIST): 
What is possible and practical? hosted by the UK National Centre for the Replacement, 
Refinement and Reduction of Animals in Research (NC3Rs; London, 4-5 March 2015). 
Participants concluded that the indirect CHO-cell based assay (i.e. the above mentioned 
modified CHO clustering assay) is a suitable alternative for replacement of HIST and 
ready for product-specific validation at manufacturer level. The results of the 
collaborative study will be published in Pharmeuropa Bio & Scientific Notes. 
Incorporation of the method into the Ph.Eur. monograph and other national and 
international regulatory requirements was recommended. The recently revised WHO 
recommendations for acellular pertussis vaccines (WHO, 2013b) already foresee the 
possible use of an alternative method to the HIST and state that if an alternative assay 
is used, it should be at least as sensitive and specific as a validated HIST assay and 
should be approved by the national regulatory authority.  
 
3.4 Specific toxicity test for whole-cell pertussis vaccines 
The test for specific toxicity (mouse weight gain test [MWGT]) is stipulated by the 
Ph.Eur. monograph for whole-cell pertussis vaccines for lot release to detect active 
pertussis toxin (EDQM, 2015g). The MWGT has been criticised for its lack of specificity, 
since not only active pertussis toxin but also other toxins (e.g. endotoxin) typically 
present in whole-cell pertussis vaccines could decrease the weight gain of mice.  
Van Straaten-van de Kapelle et al. (1997) compared in a collaborative study the 
performance of several in vitro and in vivo assays designed to detect endotoxins (in vitro 
Limulus Amoebocyte Lysate assay) or pertussis toxin (in vivo MWGT, leukocytosis 
promotion test, HIST; CHO assay). None of the tests performed well with regard to 
inter-laboratory reproducibility, most likely due to the variety of protocols used by the 
participating laboratories. The accuracy of the MWGT was lower than that of the other 
assays. Van Straaten et al. (2002) proposed to combine the mouse toxicity and 
immunogenicity test in one animal model. Specific toxicity is determined by measuring 
endotoxin levels (weight reduction 16 h post vaccination) and pertussis toxin levels 
(increase in leukocytes after 7 days), whereas serum antibody levels after 28 days are 
used as a measure of immunogenicity.  
Since the introduction of acellular pertussis vaccines in 1990s, whole-cell pertussis 
vaccines have lost their importance in Europe and other regions. However, due to the 
low production costs and since the relative protective efficacy of the best whole-cell 
pertussis and acellular pertussis vaccines are comparable, whole-cell pertussis vaccines 
remain the vaccine of choice in many developing countries. In the interest of the 3Rs, it 
might be worth to explore whether any of the methods mentioned above or those 
described in Section 3.3 is applicable for specific toxicity testing of pertussis vaccines.  
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3.5 Neurovirulence testing for lot release of live polio vaccines 
Neurovirulence testing is required for live, attenuated vaccines deriving from neurotropic 
wild-type viruses and ensures the absence of residual neurotoxicity or reversion to 
neurovirulence. In most cases, e.g. for mumps, tick-borne encephalitis, yellow fever 
vaccines, neurovirulence testing is performed during development of the vaccine; 
however, for live polio vaccine it is required also for the lot release at the bulk stage. 
Historically, non-human primates are used for neurovirulence testing (see review by 
Levenbook, 2011).  
Following the validation in a WHO-collaborative study (Dragunsky et al., 2003) in vivo 
tests based on transgenic mice carrying the human poliovirus receptor (TgPVR21 mice) 
can be used instead of non-human primates for neurovirulence testing of poliovirus 
serotypes 1, 2 and 3 (WHO, 2002; 2014c).  
Moreover, in vitro methods (mutation analysis by PCR and restriction enzyme cleavage; 
MAPREC) are available for monitoring individual mutations in each of the three poliovirus 
serotypes, which are associated with reversion to neurovirulence (see review Levenbook, 
2011). Since the MAPREC for poliovirus serotype 3 correlates well with in vivo 
neurovirulence, it is used as a screening method and only bulks passing should be tested 
in vivo (EDQM, 2015h; WHO, 2014c).  
Neverov and Chumakov (2010) propose massively parallel sequencing (MPS) for 
identifying and quantifying the mutation profiles of oral polio vaccines. As reported by 
Rubin (2011), MPS based methods may facilitate the monitoring of the genetic 
consistency of live viral vaccines, and in the case of oral polio vaccine have the potential 
to replace the in vivo neurovirulence test. The WHO announced in 2013 an international 
collaborative study that will assess the utility of massively parallel sequencing for 
monitoring molecular consistency of oral polio vaccine. The study involves national 
control authorities and vaccine manufacturers and will also develop common approaches, 
standards, and acceptance criteria needed for introduction of the new method to 
regulatory decision-making (WHO, 2013c). Preparation of the study is ongoing and 
testing will start in early 2016. 
 
4. Pyrogenicity 
The Ph.Eur. includes three methods for detection of fever inducing contaminants (i.e. 
endotoxin from gram-negative bacteria or non-endotoxin pyrogens) in vaccines: the in 
vivo pyrogen test carried out in rabbits (EDQM, 2015i), and two in vitro methods, 
namely, the bacterial endotoxin test (BET; EDQM, 2015j) and the monocyte activation 
test (MAT; EDQM, 2015k).  
The BET (or Limulus Amebocyte Lysate assay) is the appropriate test for detection of 
endotoxins from gram-negative bacteria and over the last 30 years, it replaced the 
rabbit pyrogen test in most Ph.Eur. monographs, WHO guidelines, FDA requirements for 
human vaccines. However, the BET may not be applicable to all vaccine products, since 
vaccine components as the adjuvant aluminium hydroxide may interfere with clotting 
reaction, which occurs in the presence of endotoxins.  
In contrast to the rabbit pyrogen test and the BET, the MAT is based on human cells. As 
described in Ph.Eur. 2.6.30 (EDQM, 2015k), the MAT is used to detect substances that 
activate human monocytes or monocytic cells and induce the release of cytokines. Since 
these cytokines are playing an important role in fever pathogenesis, the MAT is suitable 
to detect contamination with pyrogens. Revision of Ph.Eur. 2.6.30 is ongoing and the 
proposed new text was recently published in Pharmeuropa (EDQM, 2015l) Improvements 
to the text are based on the results of an EDQM survey carried out in 2013. It is 
underlined that the MAT is suitable, after a product-specific validation, as a replacement 
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for the rabbit pyrogen test. With regard to coverage of pyrogens, it is noted that "The 
MAT detects pyrogenic and pro-inflammatory contaminants, including endotoxins from 
gram-negative bacteria and ‘non-endotoxin’ contaminants, including pathogen-
associated molecular patterns (PAMPs), derived from gram-positive and gram-negative 
bacteria, viruses and fungi, and product-related and process-related biological or 
chemical entities."  
Several individual vaccine Ph.Eur. monographs (e.g. monographs on hepatitis B, 
meningococcal polysaccharide, pneumococcal polysaccharide, rabies, tick-borne 
encephalitis vaccines) are still listing the in vivo pyrogen test and do not refer to the 
MAT, nevertheless manufacturers and official control laboratories are encouraged to 
validate the MAT for the relevant products.  
Koryakina et al. (2014) describe the validation of the MAT using cryopreserved 
peripheral blood mononuclear cells for a vaccine "… consisting of three recombinant 
proteins and outer membrane vesicles from a gram-negative bacterium and included 
aluminum hydroxide as adjuvant."  
 
5. Potency tests 
The purpose of potency testing is to demonstrate with a suitable method that a given 
vaccine lot would induce a protective immune response comparable to that shown to be 
efficacious in humans. Depending on the type of vaccine, this may involve animal tests, 
e.g. immunisation-challenge or immunisation-serology assays for some inactivated 
vaccines, or may be carried out in vitro (antigen quantification assays for live vaccines or 
well-defined inactivated vaccines). For the immunisation-challenge assays, animals are 
immunised and after a given period infected with the virulent agent to measure 
protection against the disease. These assays are often multi-dilution assays with the 
option of using a single-dilution version. Immunisation-challenge assays may use high 
numbers of animals and involve severe pain and distress, since insufficiently protected 
animals (i.e. those which received a vaccine dilution) will develop the disease. More 
humane animal-based models for measuring potency are immunisation-serology assays, 
where animals are immunised and after a certain period the antibody levels induced by 
the vaccine are measured with an immunochemical in vitro method. 
The use of physico- and immunochemical techniques to characterise antigens and to 
apply them for the vaccine quality control has been discussed since several years in the 
light of the consistency approach (Metz et al., 2007; Hendriksen et al., 2008; De Mattia 
et al., 2011). Some of the vaccines described in the following are adjuvanted and 
possible interference with the adjuvants must be considered when developing new 
methods. 
 
5.1 Diphtheria vaccines 
The Ph.Eur. lists three possible assays for potency testing of diphtheria vaccines or 
vaccines containing a diphtheria component. It is clearly stated that the immunisation-
serology method should be preferred over the two (intra-dermal or lethal; multi- or 
single-dilution) immunisation-challenge methods (EDQM, 2015m). 
Metz et al. (2003; 2007) showed that physico- and immunochemical techniques as SDS-
PAGE, primary amino group determination, fluorescence spectroscopy, circular dichroism 
and biosensor analysis can be used to characterise diphtheria antigen and detect 
differences in experimentally produced diphtheria toxoid. The results obtained correlated 
well with the in vivo potency test. The Institute for Translational Vaccinology (Intravacc, 
NL) and Bilthoven Biologicals are currently testing (in close collaboration with the Serum 
Institute of India) 20 routinely produced lots of diphtheria toxoid at the bulk and final 
product stage with the currently regulatory required tests and a suite of additional 
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physico- and immunochemical assays (Hendriksen 2014, personal communication) as 
described by Metz et al. (2003; 2007).   
Researchers at NIBSC have developed an ELISA for diphtheria antigen quantification 
(bulk stage or after desorption of the adjuvant on the final product) and propose its use 
to demonstrate consistency of production (Coombes et al., 2009; 2012; 2015). Zhu et 
al. (2009) developed a methodology, the Direct Alum Formulation Immunoassay 
(DAFIA), which can directly demonstrate aspects of antigenic quality without prior 
desorption and used at the final product stage. This technique is part of the suite of 
assays used by Intravacc (see above). 
Validation of antigen quantification assays for diphtheria vaccines is listed in the EDQM 
BSP workprogramme for 2015 and beyond8. 
 
5.2 Tetanus vaccines 
The Ph.Eur. monograph includes two assays for potency testing of tetanus vaccines or 
vaccines containing a tetanus component. It is clearly stated that the immunisation-
serology method should be preferred over the immunisation-challenge method (EDQM, 
2015n). 
A recent publication of Metz et al. (2013) reports on the suitability of physico- and 
immunochemical methods to detect differences in the quality of ten experimentally 
produced tetanus toxoids. The authors underline that the methods still need to undergo 
validation using routinely produced vaccine lots. 
Several ELISAs have been described for quantification of tetanus antigen (Prieur et al., 
2002; Coombes et al., 2012 & 2015; Metz et al., 2013).   
Validation of antigen quantification assays for tetanus vaccines is listed in the EDQM BSP 
workprogramme for 2015 and beyond9.  
 
5.3 Whole-cell pertussis vaccines 
The potency of whole-cell pertussis vaccines is measured with an immunisation-
challenge assay known as mouse protection or Kendrick test (EDQM, 2015o; WHO, 
2007) which is highly variable, requires large number of animals and induces severe pain 
and suffering (i.e. intracerebral challenge, non-protected animals develop pertussis). The 
validation of an immunisation-serology assay is ongoing within the EDQM BSP104. In 
principle, guinea pigs are immunised with whole-cell pertussis vaccine and the level of 
induced antibodies is measured with an ELISA using whole-cell pertussis bacteria for 
coating. This assay has been developed and prevalidated in a small-scale study funded 
by the Joint Research Centre (von Hunolstein et al., 2008) and is based on the work 
carried out by van der Ark et al. (1994; 1996; 1998; 2000). 
 
5.4 Rabies 
Potency testing of rabies vaccines is carried out with a multi-dilution immunisation-
challenge assay in mice (EDQM, 2015p). The assay (also known as NIH test) has been 
criticised for many years due to its high variability, the large numbers of mice used and 
the associated severe suffering and distress. Over the last 15 years, several workshops 
have been dedicated to the use of 3Rs in the quality control of rabies vaccines e.g. 
Bruckner et al. (2003); Stokes et al. (2012). Some of the workshop recommendations as 
the use of humane endpoints in the NIH test (Bruckner et al., 2003) have been 
                                           
8 http://www.edqm.eu/en/BSP-Work-Programme-609.html 
9 http://www.edqm.eu/en/BSP-Work-Programme-609.html 
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implemented into the Ph.Eur. rabies monograph. In addition, the use of alternative 
methods to the NIH test e.g. an immunisation-serology assay or antigen quantification 
with an immunochemical assay are mentioned in the recently revised monograph 
(EDQM, 2015o), provided that they are validated against the NIH test. 
Human rabies vaccines are one of the priorities identified by the EPAA vaccines 
consistency project. In order to address the specific needs for use of the consistency 
approach and replacement of the NIH test, a workshop was organised in 2012 (see flash 
report10 on EPAA website; De Mattia et al., 2015). One critical step in the production of 
rabies vaccines is the definition of the antigen content in the final product. Manufacturers 
use in vitro antigen quantification assays for this purpose, however, due to regulatory 
requirements they need to carry out the NIH test on the final lot. There was agreement 
that an appropriate antigen quantification assay should be able to detect the native 
trimeric form of glycoprotein-G, a surface protein of the rabies virus, inducing the 
production of protective antibodies. In order to select the most suitable method for 
further validation, it was proposed to organise a collaborative study testing vaccines 
from several manufacturers and of different qualities with the methods currently in use 
by manufacturers and control laboratories.  
This study was organised by an international working group formed after the workshop 
and chaired by Jean-Michel Chapsal (formerly Sanofi Pasteur) and Noel Tordo (Institute 
Pasteur). One out of the three ELISA methods correctly estimated the antigen content of 
all vaccine samples (incl degraded samples). The results of the study and possible follow 
up have been discussed at a workshop in May 2015 (scientific paper in preparation). It 
was agreed that additional work would be needed in order to present a proposal to the 
EDQM Biological Standardisation Programme for full validation of the ELISA. 
 
6. General aspects 
6.1 Facilitate and promote product-specific validation  
Before a new method can be used for the quality control of a vaccine, it has to be 
demonstrated that the method is valid in the given laboratory for the given product. This 
process is generally known as product-specific validation and is a prerequisite for the 
acceptance of a new method, also for those included in Ph.Eur. monographs after 
validation within the BSP of EDQM. Product-specific validation is perceived as a hurdle to 
the swift implementation of 3Rs methods. In order to facilitate and promote product-
specific validation of 3Rs methods, expert groups of Ph.Eur. and the European Medicines 
Agency (EMA) are working on guidelines covering various aspects of product-specific 
validation. Whereas the Ph.Eur. group of experts 15 is focusing on guidance on data 
requirements for introducing a new method, the EMA JEG 3Rs11 group suggests in a 
recently published concept paper 12 the development of guidance on the use of data 
generated in large-scale collaborative studies (e.g. those run under EDQM BSP) for 
product-specific validation. Both documents should become available for public 
commenting in 2016. 
In this context, attention is drawn to Article 13 "Choice of Methods" of Directive 
2010/63/EU on protection of animals used for scientific purposes (EU, 2010), which 
states that that "a procedure is not carried out if another method or testing strategy for 
obtaining the result sought, not entailing the use of a live animal, is recognised under 
the legislation of the Union." DG Environment states in Questions & Answers on the legal 
                                           
10 https://circabc.europa.eu/sd/a/6cfc6e14-4c81-4981-a424-5b51b982da1d/flash-report-vaccines-workshop-
october-2012_en.pdf 
11 Joint Committee for Medicinal Products for Veterinary Use/Committee for Medicinal Products for Human Use 
Ad-hoc Expert Group on the Application of the 3Rs in Regulatory Testing of Medicinal Products (JEG 3Rs) 
12 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC50016 9977.pdf 
  
 
14 
understanding13 of Directive 2010/63/EU that The methods specified in the European 
Pharmacopoeia can be considered as "recognised by EU legislation" within the meaning 
of Article 13 of the Directive through a number of EU pieces of legislation such as 
Directives 2001/82/EC, 2001/83/EC, and 2003/63/EC, as amended, on medicines for 
human and veterinary use. If a product specific validation is a prerequisite for the use of 
such a method, the Directive does not foresee a waving from the requirement on the 
basis of time or cost. … Since a Directive gives generally the Member States some room 
for manoeuvre concerning its aims, the Competent Authority [for implementation of 
2010/63/EU] should apply the proportionality principle in their actions. The Competent 
Authority has to be satisfied that all efforts to complete the validation are made within a 
reasonable time to comply with the requirements of this Directive. Should the validation 
fail due to scientific reasons and thus the method proved not valid for the product in 
question, the use of the animal method could in those cases continue to be allowed. 
Once a successful validation is completed, or the manufacturer fails to undertake the 
validation in a reasonable time, the animal method could no longer be authorised. 
 
6.2 International harmonisation 
Due to differences in regional regulatory requirements, manufacturers may need to carry 
out different tests for lot release when marketing their products outside of Europe. One 
example is the general safety test (or ATT or test for innocuity; see Section 3.1), which 
was deleted more than 15 years ago from the Ph.Eur. monographs for lot release, but is 
still required in many countries outside of Europe.  
Several of the leading human pharmaceutical manufacturers call in their review paper 
(Garbe et al, 2014) for the removal of the ATT from pharmacopoeias and regulatory 
requirements on a global level. The ATT was introduced in the early 1900s as a test 
during production of antiserum preparations to detect the level of the preservative 
phenol. It remained in the regulatory requirements as "safety" test, however, as Garbe 
et al (2014) state, the test lacks scientific merit and is neither specific, reproducible, 
reliable, nor suitable for the intended purpose. 
The EPAA has launched a project aiming at international harmonisation of lot release 
methods (information available on the EPAA website14). Within the framework of this 
project, the EPAA convened the international workshop Modern science for better quality 
control of medicinal products: Towards global harmonisation of 3Rs in biologicals. It was 
organised by Katrin Schütte (EU Commission, Directorate General for the Environment, 
Belgium) and Anna Szczepanska (European Federation of Pharmaceutical Industries and 
Associations, Belgium) as joint leaders of the EPAA Biologicals project team and took 
place in September 2015 (report in preparation).  
Two case studies presented were related to human vaccines, the deletion of the ATT 
from national and international requirements and the use of in vitro potency assays for 
diphtheria and tetanus vaccines and the way forward to possible global acceptance of 
their use. The report of the workshop is in preparation and will become available in early 
2016. 
 
Conclusion 
The quality control of established vaccines such as diphtheria, tetanus, pertussis and 
rabies vaccines is focused on the final product control and often involves animal tests. As 
the report shows progress has been achieved and new approaches to the quality control 
as the consistency approach have the potential of further reducing animal use. 
                                           
13 http://ec.europa.eu/environment/chemicals/lab_animals/pdf/qa.pdf 
14 http://ec.europa.eu/enterprise/epaa/platform-regulation/biologicals/biologicals-project_en.htm  
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List of abbreviations and definitions  
 
3Rs   Replacement, reduction, and refinement 
ATT   Abnormal toxicity test 
BINACLE assay Binding and cleavage assay 
BET   Bacterial endotoxin test 
BSP   Biological Standardisation Programme 
cAMP   Cyclic adenosine monophosphate 
CHO cells  Chinese hamster ovary cells 
DAFIA   Direct alhydrogel formulation immunoassay 
EDQM   European Directorate for the Quality of Medicines & HealthCare 
ELISA   Enzyme-linked immunosorbent assay 
EMA   European Medicines Agency 
EPAA   European Partnership for Alternative Approaches to Animal Testing 
EU European Union 
EURL ECVAM European Union Reference Laboratory for alternatives to animal 
testing 
GST General safety test 
HIST Histamine sensitisation assay 
ICATM International Cooperation on Alternative Test Methods 
ICCVAM Interagency Coordinating Committee on the Validation of 
Alternative Methods 
IMI 2 Innovative Medicines Initiative 2 
intravacc Institute for Translational Vaccinology 
JEG 3Rs The Joint Committee for Medicinal Products for Veterinary 
Use/Committee for Medicinal Products for Human Use Ad-hoc 
Expert Group on the Application of the 3Rs in Regulatory Testing of 
Medicinal Products 
MAPREC Mutation analysis by PCR and restriction enzyme cleavage 
MAT Monocyte activation test 
MPS Massively parallel sequencing 
MWGT Mouse weight gain test 
NIBSC The National Institute for Biological Standards and Control 
NICEATM National Toxicology Program Interagency Center for the Evaluation 
of Alternative Toxicological Methods 
NC3Rs UK National Centre for the Replacement, Refinement and Reduction 
of Animals in Research 
NIH National Institute for Health 
PCR Polymerase chain reaction 
Ph.Eur. European Pharmacopoeia 
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QC Quality control 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TgPVR21 Transgenic mice carrying the human poliovirus receptor 
US FDA United States Food and Drug Administration 
WHO   World Health Organization 
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